<DOC>
	<DOCNO>NCT00006903</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth cancer cell . Hormone therapy use fulvestrant may fight cancer block uptake estrogen tumor cell . PURPOSE : This phase II trial study fulvestrant see well work treat patient recurrent , persistent , metastatic endometrial cancer .</brief_summary>
	<brief_title>Fulvestrant Treating Patients With Recurrent , Persistent , Metastatic Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare probability clinical response estrogen receptor ( ER ) -positive vs ER-negative patient recurrent , persistent , metastatic endometrial cancer treat fulvestrant . - Compare relationship response rate intensity receptor expression patient treat drug . - Determine frequency intensity toxicity drug patient . OUTLINE : Patients receive fulvestrant intramuscularly day 1 . Treatment repeat every 28 day least 2 course absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent , persistent , metastatic endometrial cancer curable surgery radiotherapy Estrogen receptor ( ER ) progesterone receptor status know immunohistochemistry ER positive negative allow Measurable disease At least 1 target lesion within previously irradiate field OR irradiate target lesion clear disease progression At least 20 mm conventional technique , include palpation , xray , CT scan , MRI , OR least 10 mm spiral CT scan PATIENT CHARACTERISTICS : Age : Not specify Performance status : GOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥100,000/mm^3 No prior bleed diathesis ( disseminated intravascular coagulation , clot factor deficiency , requirement anticoagulant ) Hepatic : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 3 time ULN Alkaline phosphatase ≤ 3 time ULN Renal : Creatinine ≤ 2 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No hypersensitivity castor oil No concurrent malignancy except nonmelanoma skin cancer No prior malignancy within past 5 year PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy persistent , recurrent , metastatic endometrial cancer No 1 prior chemotherapy regimen newly diagnose endometrial cancer subsequently recur Endocrine therapy : At least 3 week since prior hormonal therapy recover Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover Surgery : See Disease Characteristics At least 3 week since prior surgery recover</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
</DOC>